Skip to content

Innovative Medicine
healthcare areas

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again

      1. Innovative Medicine /
      2. Neuroscience /
      3. Alzheimer’s disease
      JJ_BodyIllustration_Interior_Organ_BrainProfile_Colorway03 8.32.53 AM.jpg

      Alzheimer’s disease

      Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that leads to memory loss and a decline in cognitive abilities so severe that they significantly interfere with daily life. Tens of millions of people are living with cognitive symptoms of AD, and hundreds of millions more may have tau and amyloid pathology – the hallmark proteins associated with the disease – starting to accumulate in their brains potentially decades before clinical signs emerge.

      As symptoms progress, AD imposes a significant burden on patients, caregivers, health systems, and society. It is among the top 10 leading causes of death globally, with its economic toll projected to reach nearly $3 trillion by 2030.

      Alzheimer’s is among the top 10 leading causes of death globally, with its economic toll projected to reach nearly $3 trillion by 2030.

      J&J’s approach to Alzheimer’s disease

      For decades, we’ve been committed to researching and developing potential treatments for Alzheimer’s disease. Guided by a legacy of innovation and scientific progress, we continue to deepen our understanding of the disease and advance tools that may enable earlier, more targeted intervention. Today, we’re applying this knowledge through a precision-based, multi-pronged approach to address the full complexity of Alzheimer’s disease.

      Our research spans the full continuum of the disease — preventing cognitive decline in its earliest stages, developing therapies that slow disease progression, and addressing neuropsychiatric symptoms in more advanced stages. We’re also exploring tools to identify and diagnose the disease earlier and more definitively, recognizing that detecting disease pathology before symptoms appear is essential to changing the course of the disease.

      Explore

      Learn more about medicines and therapies for Alzheimer’s disease and other diseases

      More from Johnson & Johnson

      Could we be on the cusp of catching Alzheimer’s before it starts?

      The key to slowing cognitive decline is diagnosing the disease as early as possible. And that’s exactly what Johnson & Johnson scientists are relentlessly pursuing.

      Alzheimer’s disease: Why one company refuses to give up the search for a cure

      It’s the sixth leading cause of death in the United States, with no existing cure. But these researchers are committed to finding better ways to diagnose, treat and prevent the debilitating disease, using everything from innovative biomarker tracking to a potential vaccine for early stage patients.

      3 groundbreaking ways researchers are rethinking Alzheimer’s disease

      Diagnostic tests. Clinical trials. A vaccine. For Alzheimer’s Awareness Month, we sat down with scientists at Janssen Research & Development to learn how their work has the potential to alter the future of how we detect and treat the disease.